Lessons derived from this condition may ultimately inform not only the management of melorheostosis but also the development of targeted interventions for more common skeletal disorders in which MAPK and TGF‐β signaling play critical roles, including osteoporosis and metabolic sclerosing dysplasias. This evidence concerns the gene TGFB1 and melorheostosis.